[{"orgOrder":0,"company":"PPD","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"RQ-001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"6","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"AEON Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"8","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Immunology","graph2":"Approved FDF","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"15","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"10","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ocrelizumab","moa":"B-lymphocyte antigen CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"15","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"Theratechnologies","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"6","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Radiolabeled Compounds","year":"2020","type":"Inapplicable","leadProduct":"Ioflupane","moa":"Dopamine transporter (DAT)","graph1":"Undisclosed","graph2":"Phase I","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"6","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"Angelini Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Benzydamine Hydrochloride","moa":"Cyclooxygenase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Gargle\/Mouthwash","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"11","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"Liquidia Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"10","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Immediate Release","sponsorNew":"PPD \/ First Wave BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"PPD \/ First Wave BioPharma"},{"orgOrder":0,"company":"PPD","sponsor":"Altavant Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rodatristat Ethyl","moa":"Tryptophan 5-hydroxylase 1","graph1":"Undisclosed","graph2":"Phase I","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"6","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pacritinib","moa":"Tyrosine-protein kinase receptor FLT3 | Tyrosine-protein kinase JAK2","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"6","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"Dizal Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sunvozertinib","moa":"EGFR Exon20ins mutant (EGFR Exon20ins)","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"6","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Niclosamide","moa":"DNA","graph1":"Immunology","graph2":"IND Enabling","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"PPD \/ First Wave BioPharma","highestDevelopmentStatusID":"5","companyTruncated":"PPD \/ First Wave BioPharma"},{"orgOrder":0,"company":"PPD","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Bepirovirsen","moa":"mRNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"8","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PPD \/ Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech","highestDevelopmentStatusID":"8","companyTruncated":"PPD \/ Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech"},{"orgOrder":0,"company":"PPD","sponsor":"Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Paridiprubart","moa":"TLR4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PPD \/ Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech","highestDevelopmentStatusID":"8","companyTruncated":"PPD \/ Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech"},{"orgOrder":0,"company":"PPD","sponsor":"Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ifx-1","moa":"Complement C5","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PPD \/ Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech","highestDevelopmentStatusID":"8","companyTruncated":"PPD \/ Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech"},{"orgOrder":0,"company":"PPD","sponsor":"Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ifx-1","moa":"Complement C5","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PPD \/ Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech","highestDevelopmentStatusID":"8","companyTruncated":"PPD \/ Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech"},{"orgOrder":0,"company":"PPD","sponsor":"Versameb","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"VMB-100","moa":"Undisclosed","graph1":"Urology","graph2":"Phase II","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"8","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"AEON Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ABP-450","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase II","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"8","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"AEON Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ABP-450","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"8","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"AEON Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ABP-450","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase II","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"8","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"COVID-19 Vaccine, mRNA","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"8","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Granisetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"6","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Depemokimab","moa":"Interleukin-5","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"10","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"CYP450","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PPD \/ PPD","highestDevelopmentStatusID":"6","companyTruncated":"PPD \/ PPD"},{"orgOrder":0,"company":"PPD","sponsor":"US Army","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PPD \/ US Army","highestDevelopmentStatusID":"1","companyTruncated":"PPD \/ US Army"}]

Find Clinical Drug Pipeline Developments & Deals by PPD

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Lead Product(s) : Ifx-1

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Study Phase : Phase II

                          Sponsor : Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          November 25, 2024

                          Lead Product(s) : Ifx-1

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Lead Product(s) : Bevacizumab

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Study Phase : Phase II

                          Sponsor : Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          November 22, 2024

                          Lead Product(s) : Bevacizumab

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Lead Product(s) : Paridiprubart

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Study Phase : Phase II

                          Sponsor : Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          November 22, 2024

                          Lead Product(s) : Paridiprubart

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Lead Product(s) : Ifx-1

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Study Phase : Phase II

                          Sponsor : Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          November 22, 2024

                          Lead Product(s) : Ifx-1

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Biomedical Advanced Research and Development Authority | InflaRx | Edesa Biotech | Genentech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          September 19, 2024

                          Lead Product(s) : Anifrolumab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase IV

                          Recipient : AstraZeneca

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : ABP-450 (prabotulinumtoxin A) is an investigational, 900 kDa botulinum toxin type A complex, which acts as a SNAP inhibitor indicated for the treatment of cervical dystonia.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          September 07, 2024

                          Lead Product(s) : Prabotulinumtoxin A

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase II

                          Recipient : AEON Biopharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          May 21, 2024

                          Lead Product(s) : Bepirovirsen

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Recipient : GSK

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          February 07, 2024

                          Lead Product(s) : VMB-100

                          Therapeutic Area : Urology

                          Highest Development Status : Phase II

                          Recipient : Versameb

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 16, 2023

                          Lead Product(s) : Sunvozertinib

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase I

                          Recipient : Dizal Pharmaceutical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          October 02, 2023

                          Lead Product(s) : RQ-001

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Recipient : PPD

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank